Systematic Reviews
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatr. Jul 19, 2020; 10(7): 162-174
Published online Jul 19, 2020. doi: 10.5498/wjp.v10.i7.162
Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review
Shilpa Srinivasan, Rajesh R Tampi, Kripa Balaram, Arushi Kapoor
Shilpa Srinivasan, Department of Neuropsychiatry and Behavioral Science, Palmetto Health USC Medical Group, University of South Carolina School of Medicine, Columbia, SC 29203, United States
Rajesh R Tampi, Department of Psychiatry and Behavioral Sciences, Cleveland Clinic Akron General, Akron, OH 44307, United States
Rajesh R Tampi, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 44195, United States
Kripa Balaram, MD, Department of Psychiatry, MetroHealth, Cleveland, OH 44109, United States
Arushi Kapoor, Penn Memory Center at the Penn Neuroscience Center, Perelman Center for Advanced Medicine, Philadelphia, PA 19104, United States
Author contributions: All authors contributed to this work.
Conflict-of-interest statement: All the authors declare that they have no competing interests.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Shilpa Srinivasan, MD, Doctor, Professor, Department of Neuropsychiatry and Behavioral Science, Palmetto Health USC Medical Group, University of South Carolina School of Medicine, 3555 Harden Street Extension, Suite 301, Columbia, SC 29203, United States.
Received: February 13, 2020
Peer-review started: February 13, 2020
First decision: April 3, 2020
Revised: May 25, 2020
Accepted: June 10, 2020
Article in press: June 10, 2020
Published online: July 19, 2020
Core Tip

Core tip: This systematic review was conducted to evaluate the evidence from randomized controlled clinical trials of pimavanserin for the treatment of psychosis in individuals with Alzheimer’s disease (AD). Behavioral disturbances including psychosis are prevalent in AD, and have a significant impact on management and outcomes. There are currently no United States Food and Drug Administration approved medications for the management of behavioral disturbance in AD. Based on the findings of our systematic review, pimavanserin, a novel atypical antipsychotic, may be a new pharmacologic consideration for treating psychosis in individuals with AD.